Unstimulated and Anti-CD40–Stimulated IgG, IgA, and IgM Levels in PBMCs and Purified B-Lymphocyte Culture Supernatants From 8 Patients With HIV Infection (All in Clinical Stage CDC A) and From 10 HIV-Seronegative Blood Donors
| . | PBMC . | B Lymphocytes . | |||
|---|---|---|---|---|---|
| Unstimulated . | +Anti-CD40 . | Ratio . | Unstimulated . | +Anti-CD40 . | |
| IgG | |||||
| HIV+ | 2,487* (1,036-5,085) | 4,535† (4,111-7,898) | 2.59 (1.33-4.26) | 2 (0-7) | 3,322† (3,003-5,549) |
| Controls | 843 (597-1,016) | 2,974 (2,536-3,337) | 3.53 (2.64-5.59) | 15 (0-40) | 2,138 (1,891-2,526) |
| IgA | |||||
| HIV+ | 2,043† (1,494-5,695) | 3,031* (1,547-7,148) | 1.10 (0.94-1.27) | 6 (0-18) | 45 (0-100) |
| Controls | 352 (208-1,321) | 584 (332-1,376) | 1.38 (1.0-1.63) | 7 (4-20) | 11 (8-29) |
| IgM | |||||
| HIV+ | 165 (113-431) | 187† (141-449) | 1.15 (0.91-1.31) | 0 (0-4) | 6 (0-11) |
| Controls | 85 (46-146) | 73 (39-120) | 0.88 (0.65-1.12) | 0 (0-6) | 5 (3-10) |
| . | PBMC . | B Lymphocytes . | |||
|---|---|---|---|---|---|
| Unstimulated . | +Anti-CD40 . | Ratio . | Unstimulated . | +Anti-CD40 . | |
| IgG | |||||
| HIV+ | 2,487* (1,036-5,085) | 4,535† (4,111-7,898) | 2.59 (1.33-4.26) | 2 (0-7) | 3,322† (3,003-5,549) |
| Controls | 843 (597-1,016) | 2,974 (2,536-3,337) | 3.53 (2.64-5.59) | 15 (0-40) | 2,138 (1,891-2,526) |
| IgA | |||||
| HIV+ | 2,043† (1,494-5,695) | 3,031* (1,547-7,148) | 1.10 (0.94-1.27) | 6 (0-18) | 45 (0-100) |
| Controls | 352 (208-1,321) | 584 (332-1,376) | 1.38 (1.0-1.63) | 7 (4-20) | 11 (8-29) |
| IgM | |||||
| HIV+ | 165 (113-431) | 187† (141-449) | 1.15 (0.91-1.31) | 0 (0-4) | 6 (0-11) |
| Controls | 85 (46-146) | 73 (39-120) | 0.88 (0.65-1.12) | 0 (0-6) | 5 (3-10) |